INDICATIONS AND USAGE

Gadobutrol Injection is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI):

Contraindications: Gadobutrol Injection is contraindicated in patients with history of severe hypersensitivity reaction to Gadobutrol Injection.

Hypersensitivity Reactions: Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory, or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred following Gadobutrol Injection administration. Before Gadobutrol Injection administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to Gadobutrol Injection. Administer Gadobutrol Injection only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation.

Gadolinium Retention: Gadolinium is retained for months or years in brain, bone, and other organs. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, retention varies among the linear agents. Retention is lowest and similar among the macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function. While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent and minimize repetitive GBCA studies, when possible.

Acute Kidney Injury: In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of GBCAs. Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses.

Extravasation and Injection Site Reactions: Ensure catheter and venous patency before the injection of Gadobutrol Injection. Extravasation into tissues during Gadobutrol Injection administration may result in moderate irritation.

Overestimation of Extent of Malignant Disease in MRI of the Breast: Gadobutrol Injection MRI of the breast overestimated the histologically confirmed extent of malignancy in the diseased breast in up to 50% of the patients.

Low Sensitivity for Significant Arterial Stenosis: The performance of Gadobutrol Injection MRA for detecting arterial segments with significant stenosis (>50% renal, >70% supra-aortic) has not been shown to exceed 55%. Therefore, a negative MRA study alone should not be used to rule out significant stenosis.

Adverse Events: The most frequent (≥ 0.5%) adverse reactions associated with Gadobutrol Injection in clinical studies were headache (1.7%), nausea (1.2%) and dizziness (0.5%).

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy: GBCAs cross the placenta and result in fetal exposure and gadolinium retention. Because of the potential risks of gadolinium to the fetus, use Gadobutrol Injection only if imaging is essential during pregnancy and cannot be delayed.

This Important Safety Information does not include all the information needed to use Gadobutrol Injection, USP safely and effectively. Please see full prescribing information, including BOXED WARNING, for Gadobutrol Injection single dose vials and imaging bulk package. Full prescribing information is also available at www.fresenius-kabi.com/us.